“Viltolarsen was negative in a standard battery of in vitro (Ames, chromosomal aberration in CHL cells) and in vivo (mouse micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
Carcinogenicity
Not conducted pre-approval (agreed); rasH2 mouse and 2-year rat studies as PMRs
“Carcinogenicity studies of viltolarsen were not submitted to the NDA, as agreed to by the Division.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Male mouse fertility study only (no effects); EFD/PPND waived for male population; juvenile mouse study
“Embryofetal development and pre- and postnatal development studies were not conducted, as agreed to by the Division, because of the intended patient population, which is almost exclusively male.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Safety pharmacology
Dedicated single-dose studies: rat CNS (FOB), monkey CV/respiratory, in vitro hERG; no effects
“Dedicated single dose studies in rat (CNS) and monkey (cardiovascular and respiratory) did not indicate drug effects on safety pharmacology endpoints, and there was no effect on QT prolongation in CHO cell cultures exposed to up to 3 mg/mL vitolarsen.”
✓ VerifiedFDA pharmacology/toxicology review, p. 47Source ↗
Genotox: Ames
Negative
“Viltolarsen was negative for genotoxicity in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster lung cells) and in vivo (mouse bone marrow micronucleus) assays.”
Chromosomal aberration in Chinese hamster lung cells: negative
“Viltolarsen was negative for genotoxicity in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster lung cells) and in vivo (mouse bone marrow micronucleus) assays.”
“Viltolarsen was negative for genotoxicity in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster lung cells) and in vivo (mouse bone marrow micronucleus) assays.”
Not conducted; SPA protocols for 26-week Tg.rasH2 mouse and 2-year rat reviewed by the Division and Executive CAC
“Protocols for a 26-week study in Tg.rasH2 mouse and a 2-year study in rat were submitted for review under Special Protocol Assessment and were reviewed by the Division and the Executive CAC under IND 127474 (Minutes dated July 12, 2018, and August 9, 2019, respectively).”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Carcinogenicity timing
Not conducted before approval; 26-week Tg.rasH2 mouse and 2-year rat studies are postmarketing requirements
“If the application is approved, a 26-week carcinogenicity study in Tg.rasH2 mouse and a 2-year carcinogenicity study in rat should be conducted as PMRs.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
hERG / QT
No hERG/QT effect in CHO cells up to 3 mg/mL; no effects in rat CNS and monkey CV/respiratory studies
“Dedicated single dose studies in rat (CNS) and monkey (cardiovascular and respiratory) did not indicate drug effects on safety pharmacology endpoints, and there was no effect on QT prolongation in CHO cell cultures exposed to up to 3 mg/mL vitolarsen.”
✓ VerifiedFDA pharmacology/toxicology review, p. 47Source ↗